Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | APG-1252 + APG-2575 + Cytarabine + Filgrastim + Fludarabine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| APG-1252 | BM-1252|Pelcitoclax|APG1252|APG 1252 | BCL-XL inhibitor 14 BCL2 inhibitor 29 | Pelcitoclax (APG-1252) inhibits BCL2 and BCL-XL, which potentially leads to tumor growth inhibition (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 9116). | |
| APG-2575 | APG 2575|APG2575|Lisaftoclax | BCL2 inhibitor 29 | APG-2575 is a small molecule that inhibits BCL-2, potentially resulting in increased apoptosis and enhanced antitumor activity in combination with other agents (PMID: 32093809, PMID: 37074726). | |
| Cytarabine | Cytosar-U | Ara-C | Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309). | |
| Filgrastim | Neupogen | G-CSF | Neupogen (filgrastim) is a recombinant analog of granulocyte colony-stimulating factor (G-CSF) isoform B, which binds and activates G-CSF receptors modulating neutrophilic granulocyte progenitor activity, production, and differentiation (NCI Drug Dictionary). | |
| Fludarabine | Fludara | FAMP|Fludarabine phosphate | Fludara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary) |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07428486 | Phase I | APG-1252 + APG-2575 + Cytarabine + Filgrastim + Fludarabine | A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia | Not yet recruiting | USA | 0 |